Protocol Ledger

NCT03976076 · Phase II · TERMINATED

A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients

Interventional Phase II clinical trial protocol NCT03976076 sponsored by Bio-Pharm Solutions Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-04-15 Enrollment: 16 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03976076
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)16 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03976076
Protocol FieldVerified Registry Value
NCT IdentifierNCT03976076
Consolidated Lead SponsorBio-Pharm Solutions Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment16 participants (ACTUAL)
Registered Start Date2020-04-15
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI